Back to search
FDAFDA · Food and drugs·Recall number D-0139-2026

Everolimus tablets 5mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-125-91

Published November 5, 2025 · Recall initiated: October 10, 2025

Summary

FDA records drug Class III recall D-0139-2026, published November 5, 2025 and initiated October 10, 2025. Recalling firm: Endo USA, Inc.; Status: Ongoing; Reported quantity: 6,655 cartons; Lot: Lot #: 550184901, 550185001, Exp. Date MAR-26; 550189901, 550190001, Exp. Date APR-26 550203901, 550205601, Exp. Date Jul-26. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Endo USA, Inc.
Distributor
Nationwide within the United States
Lot
Lot #: 550184901, 550185001, Exp. Date MAR-26; 550189901, 550190001, Exp. Date APR-26 550203901, 550205601, Exp. Date Jul-26
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Everolimus tablets 5mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-125-91 recalled?

Yes. FDA published recall D-0139-2026 on November 5, 2025. Reported hazard: Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.

What should I do if I have this product?

Voluntary: Firm initiated · Letter